Daclatasvir Dihydrochloride

盐酸达拉他韦

Report date: 2026/03/14 20:00:17
NMEFirst In Class

Base Information

Drug NameDaclatasvir Dihydrochloride
Drug Alias Name盐酸达卡拉伟Daclatasvirum达拉他韦达卡他韦达卡他伟 +[11] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionNonstructural protein 5A inhibitors
TargetsNonstructural protein 5A
Therapy Area/IndicationsLiver CirrhosisHepatic InsufficiencyHepatitis C, Chronic +[5] 
Global Approved IndicationsHepatitis C
Approved Indications in ChinaHepatitis C
Original Approved Country/TerritoryJapan
Original Approved Date2014/07/04
Country/TerritoryBelgiumCanadaUnited States +[35] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesBristol-Myers Squibb Company
China Registration ClassN/A

Develop Information

Active CompaniesBristol-Myers Squibb (China) Investment Co LtdBristol-Myers Squibb (Singapore) Pte LtdBristol-Myers Squibb Company
Inactive CompaniesBristol Myers Squibb SrlcompanyGenuine Research Center, EgyptGlaxosmithkline Plc +[5] 
Active IndicationsHepatitis C, ChronicHepatitis C
Inactive IndicationsLiver CirrhosisHepatic InsufficiencyHIV Infections

Other Information

ATC CodeJ05AP07
Related LinksWikipediaDrugBankKEGG